Baillie Gifford - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baillie Gifford ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q1 2023$967
-68.9%
1,3760.0%0.00%
Q4 2022$3,110
-22.2%
1,3760.0%0.00%
Q3 2022$4,000
-20.0%
1,3760.0%0.00%
Q2 2022$5,000
-28.6%
1,3760.0%0.00%
Q1 2022$7,000
-63.2%
1,3760.0%0.00%
Q4 2021$19,000
-24.0%
1,3760.0%0.00%
Q3 2021$25,000
-3.8%
1,376
-10.8%
0.00%
Q2 2021$26,000
-16.1%
1,5420.0%0.00%
Q1 2021$31,000
+19.2%
1,542
+2.1%
0.00%
Q4 2020$26,0001,5110.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q1 2021
NameSharesValueWeighting ↓
Camber Capital Management LP 5,000,000$82,950,0002.19%
MAVERICK CAPITAL LTD 5,678,221$94,202,0001.75%
Rhenman & Partners Asset Management AB 1,000,000$16,590,0001.48%
Goodman Financial Corp 119,198$1,977,0000.92%
Bellevue Group AG 3,632,358$60,261,0000.83%
OSTERWEIS CAPITAL MANAGEMENT INC 477,004$7,914,0000.53%
Parametrica Management Ltd 13,658$226,0000.43%
RICE HALL JAMES & ASSOCIATES, LLC 592,930$9,837,0000.40%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 67,000$1,110,0000.36%
Burleson & Company, LLC 92,836$1,617,0000.31%
View complete list of NEKTAR THERAPEUTICS shareholders